I don't see it on the website.
well, let's see how long we have to wait
I think Huawei and samsung or Xiaomi will get much more market shares in the world!
I trust Dan, I believe LM science, no regret put all money in Advaxis, just wait and see!
Paris (AFP) - French pharmaceutical giant Sanofi said Thursday it had made a bid to acquire Medivation in a deal valuing the US cancer drug firm at around $9.3 billion (8.2 billion euros).
Under terms of the offer, Sanofi would pay $52.50 per share in cash for the San Francisco-based firm, which specialises in cancer treatments.
If the bid is accepted, it would be Sanofi's biggest acquisition since it bought the US biotech group Genzyme in 2011 for more than $20 billion.
"Thanks to Medivation's excellent prostate cancer treatments, we believe that a merger with Medivation would benefit patients and, at the same time, create value for shareholders in both companies," said Sanofi's chief executive Olivier Brandicourt in a statement.
Sanofi is the 11th largest pharmaceutical company in the world by stock market valuation and the second biggest firm in France after oil giant Total with a market capitalisation which stood at around 100 billion euros on Thursday.
This is what I'm talking about! Time will come for Advaxis!
Stemcentrx, a startup with backing from Silicon Valley investors including Artis Ventures and Founders Fund, was just acquired by AbbVie for $5.8 billion in cash and stock.
to this. with combo data with medImmune, combo data with merck on the way 2H 2016, we could break triple digit by November, I think both data could add $3-4$ billion MC, IMHO.
Sentiment: Strong Buy
last march 2015 he said don't buy, stock went up to $30.00
That's the reason we are here!
I just hope our Adxs can make some money for us this year. good luck!
IMO at least double or triple , we are looking at $20-$40 range. If the data outstanding, big hedge could bring this to $50 possible, don't forget Puma up $150 in one day. It all depends how the Hedge play this time. This time is not like last year. we are a better built company today.
Sentiment: Strong Buy
New York, NY (PRWEB) April 04, 2016
Oral, head, and neck cancers are among the fastest rising cancers today. Each year they account for more than 110,000 new cases in the United States and 550,000 cases worldwide, according to the American Academy of Otolaryngology – Head and Neck Surgery. These numbers include tongue and throat cancers caused by the human papillomavirus (HPV), as well as other forms of cancer caused by tobacco use. April 10-16 is Oral, Head & Neck Cancer Awareness Week®. Mount Sinai experts are sharing tips on prevention and urging the community to get screened.
"Research has shown that patients who have oropharyngeal cancer caused by HPV and receive timely treatment survive considerably longer than those who are diagnosed later in the disease process," said Brett Miles, MD, DDS, Associate Professor of Otolaryngology at the Icahn School of Medicine at Mount Sinai. "Catching the disease at the earliest possible stage is crucial for good outcomes and improved survival, although fortunately, we now have several novel treatment strategies which can help patients survive considerable time even in advanced stages of the disease."
Data Evaluating KEYTRUDA as a Single Agent and in Novel Combinations Across a Wide Range of Cancers to Be Presented
someone said on the board before